• Veerappan Subramaniyam, Edmund K Waller, Jonathan R Murrow, Amita Manatunga, Sagar Lonial, Karthikeswar Kasirajan, Diane Sutcliffe, Wayne Harris, W Robert Taylor, R Wayne Alexander, and Arshed A Quyyumi.
• Division of Cardiology, Emory University School of Medicine, 1364 Clifton Rd., Atlanta, GA 30322, USA.
• Am. Heart J. 2009 Jul 1;158(1):53-60.e1.

BackgroundWe hypothesized that granulocyte macrophage colony-stimulating factor (GM-CSF) administration will be safe and will improve endothelial dysfunction and exercise capacity by mobilizing progenitor cells in patients with peripheral arterial disease (PAD).MethodsForty-five patients with PAD received thrice-weekly injections for 2 weeks of 3, 6, or 10 microg/kg per day of GM-CSF or placebo in successive cohorts of 15 subjects randomized 2:1 to drug or placebo. CD34+ mononuclear cell subsets and colony formation assay, endothelial function, ankle-brachial index, and walking capacity were measured.ResultsGranulocyte macrophage colony-stimulating factor administration was safe. After pooling data from GM-CSF cohorts, at 2 weeks, there was a significant increase in total leukocytes (43%, P < .0001), CD34+ cells (46%, P = .035), and colony-forming units (31%, P = .026, week 1). At 12 weeks, endothelial function improved with GM-CSF (flow-mediated vasodilation increased by 59%, P < .01) as did pain-free treadmill walking time (38 seconds, P = .008) and total treadmill walking time (55 seconds, P = .016). Corresponding changes were not observed in the placebo group.ConclusionsGranulocyte macrophage colony-stimulating factor therapy in patients with PAD was associated with mobilization of progenitor cells, improvement of endothelial dysfunction, and exercise capacity. The efficacy of strategies designed to mobilize bone marrow progenitors warrants further study in patients with PAD.

29 keywords...

hide…